Precigen's third quarter 2026 revenue reached $74.1M as PAPZIMEOS drove early positive cash flow

Precigen reported total revenue of $74.1 million for the third quarter of 2026, a significant increase from the prior year following the commercial launch of PAPZIMEOS. The company achieved positive cash flow a full quarter ahead of management's previous guidance, supported by robust product uptake and disciplined spending.

Key Highlights

• PAPZIMEOS net revenue grew 37% sequentially to $72.96 million, with more than 500 patients having initiated treatment to date.
• Achieved positive operating cash flow of $11.9 million, reaching this milestone ahead of the previously guided year-end target.
• Net income for the quarter was $35.8 million, or $0.08 per diluted share, compared to a net loss of $325.3 million in the prior year period.